Mein Warenkorb

Cathepsin L

Cathepsin L Molekülinformation

Englischer NameCathepsin LAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel0Target-AliasCathepsin L1,CATL,CTSL,MEP,EC:3.4.22.15,CTSL1,Major Excreted Protein,Cathepsin L,FLJ31037
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameCathepsin L
Target-AliasCathepsin L1,CATL,CTSL,MEP,EC:3.4.22.15,CTSL1,Major Excreted Protein,Cathepsin L,FLJ31037
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel0
Höchste Forschungs- und EntwicklungsphaseApproved

Cathepsin L Produktliste

  • Attribut

    Protein (3)

  • Produktbibliothek

    Online (3)

  • Spezies

    Mouse (1)Human (2)

  • Etikett

    His Tag (2)Tag Free (1)

  • Marker

    Unconjugated (3)

Cathepsin L Molekülhintergrund

Cathepsin L (CTSL1) is also known as major excreted protein (MEP), is a member of the peptidase C1 family, is a dimer composed of disulfide-linked heavy and light chains linked by disulfide bonds. CTSL1 is a lysosomal cysteine proteinase that plays a major role in intracellular protein catabolism. Its substrates include collagen and elastin, as well as alpha-1 protease inhibitor, a major controlling element of neutrophil elastase activity. MEP has been implicated in several pathologic processes, including myofibril necrosis in myopathies and in myocardial ischemia, and in the renal tubular response to proteinuria. CTSL1 is important for the overall degradation of proteins in lysosomes. The specificity of MEP is close to that of papain. As compared to cathepsin B, cathepsin L exhibits higher activity toward protein substrates, but has little activity on Z - Arg – Arg – NHMec, and no peptidyl - dipeptidase activity. Human Cathepsin L activity is greatest under mildly acidic conditions, from pH 4.5 ­ 6.5. The stability of the enzyme decreases at higher pH values

Cathepsin L Molekülalias

CTSL1,MEP,CATL,CTSL

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
OlgotrelvirSTI-1558; STI1558ApprovedTexas A&M UniversityOvydso, 奥维宁Mainland ChinaCoronavirus Disease 2019 (COVID-19)Zhejiang Acea Pharmaceutical Co Ltd2025-10-28Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
Kontaktieren Sie uns